Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Frontage Laboratories, Inc.

    Client Virtual Booth

    FRONTAGE LABORATORIES, INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Frontage Laboratories, Inc
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    700 Pennsylvania Drive Exton, PA 19341
    Telephone
    Telephone
    1 610 232 0100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.frontagelab.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

    Details:

    Ketamir-2 is a novel oral ketamine analog which could potentially deliver ultra-rapid antidepressant effects by inhibiting NMDA receptor. It is being evaluated for the treatment of major depressive disorder with suicidal ideation & treatment-resistant depression.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Mira Pharmaceuticals

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 02, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Frontage Partners with Eisai and Biogen to Complete the Clarity AD Study for the Alzheimer's Drug, Lecanemab

    Details:

    BAN2401 (lecanemab) is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils, being developed for Alzheimer's disease (AD).


    Lead Product(s): Lecanemab

    Therapeutic Area: Neurology Product Name: BAN201

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Eisai

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership December 12, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search